B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CYBB

MOLECULAR TARGET

cytochrome b-245 beta chain

UniProt: P04839NCBI Gene: 15367 compounds

CYBB (cytochrome b-245 beta chain) is targeted by 7 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CYBB

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1ebselen4.74113
2diphenyleneiodonium chloride2.4811
3Luteolin 5,7,3',4'-tetrahydroxy-flavone,1.956
4Apigenin 5,7,4'-trihydroxy-flavone,1.614
5chrysin1.614
6celastrol0.691
7Naloxone0.691

About CYBB as a Drug Target

CYBB (cytochrome b-245 beta chain) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 7 compounds with documented CYBB interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CYBB inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.